Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®)-Reference-Cited by-同舟云学术

Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®)

Published:2014-06-26 Issue:3 Volume:74 Page:457-463
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Boers-Sonderen Marye J.,van Herpen Carla M. L.,van der Graaf Winette T. A.,Desar Ingrid M. E.,van der Logt Mirjam G. W. Arens-,de Beer Yvo M.,Ottevanger Petronella B.,van Erp Nielka P.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-014-2514-9.pdf

Reference29 articles.

1. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312–3322

2. Gordon AN, Tonda M, Sun S, Rackoff W (2004) Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95:1–8

3. Keller AM, Mennel RG, Georgoulias VA, Nabholtz J-M, Erazo A, Lluch A, Vogel CL, Kaufmann M, von Minckwitz G, Henderson IC, Mellars L, Alland L, Tendler C (2004) Randomized Phase III Trial of Pegylated Liposomal Doxorubicin Versus Vinorelbine or Mitomycin C Plus Vinblastine in Women With Taxane-Refractory Advanced Breast Cancer. J Clin Oncol 22:3893–3901

4. Muggia FM, Blessing JA, Sorosky J, Reid GC (2002) Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 20:2360–2364

5. Cianfrocca M, Lee S, Von Roenn J, Tulpule A, Dezube BJ, Aboulafia DM, Ambinder RF, Lee JY, Krown SE, Sparano JA (2010) Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer 116:3969–3977

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of formulation parameters and circulation time on PEGylated liposomal doxorubicin related hand-foot syndrome;International Journal of Pharmaceutics;2024-11

2. Population pharmacokinetics and toxicity correlation analysis of free and liposome-encapsulated doxorubicin in Chinese patients with advanced breast cancer;Cancer Chemotherapy and Pharmacology;2023-06-28

3. Revisiting the outstanding questions in cancer nanomedicine with a future outlook;Nanoscale Advances;2022

4. The prognosis of cancer patients undergoing liposomal doxorubicin-based chemotherapy;Medicine;2021-08-27

5. Comparative Evaluation of Cellular Uptake of Free and Liposomal Doxorubicin Following Short Term Exposure;Anticancer Research;2021-05